Here are what the editors at HealthDay consider to be the most important developments in Urology for May 2010. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Higher Varicocele Grade Linked to Lower Sperm Density
FRIDAY, May 28 (HealthDay News) -- In men with varicocele and infertility, the grade of the varicocele is related to semen quality, and grade III varicoceles are associated with higher testosterone levels, according to research published in the May issue of Urology.
Abstract
Full Text (subscription or payment may be required)
Analysis Questions Quality of Direct-to-Consumer Ads
THURSDAY, May 27 (HealthDay News) -- Direct-to-consumer advertising (DTCA) for urological medications lacks research data or references to substantiate the claims they make, pointing to room for improvement in the information offered by such advertisements, according to an analysis published in the May issue of Urology.
Abstract
Full Text (subscription or payment may be required)
Antibiotic Resistance May Persist Months After Treatment
WEDNESDAY, May 19 (HealthDay News) -- After a course of antibiotics for respiratory or urinary tract infection, an individual is likely to develop resistance to the antibiotic that may persist for up to 12 months, according to research published online May 18 in the BMJ.
Abstract
Full Text
Kidney Function Measures Predict Risk of Death
TUESDAY, May 18 (HealthDay News) -- In the general population, a low estimated glomerular filtration rate (eGFR) and a high urine albumin-to-creatinine ratio (ACR) are independent predictors of mortality, according to an analysis published online May 18 in The Lancet.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
In Prostate Cancer, Selective Alendronate Use Cost-Effective
TUESDAY, May 18 (HealthDay News) -- A bone mineral density test followed by selective use of alendronate for fracture prevention in men beginning androgen deprivation therapy for localized prostate cancer is cost-effective, according to research published in the May 18 issue of the Annals of Internal Medicine.
Abstract
Full Text (subscription or payment may be required)
Many Have Low Distress During Prostate Cancer Surveillance
MONDAY, May 17 (HealthDay News) -- Men with low-risk prostate cancer on active surveillance generally have favorably low anxiety and distress in the first nine months of surveillance, according to research published in the May issue of The Journal of Urology. Another article in the same issue examines how health status and life expectancy influenced selection of men age 75 and older for prostate-specific antigen (PSA) screenings before the United States Preventive Services Task Force (USPSTF) recommended against screening them.
Abstract- van den Bergh
Full Text (subscription or payment may be required)
Abstract - Hoffman
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Common Diagnostic Tests for UTI Miss Many Infections
MONDAY, May 17 (HealthDay News) -- Commonly used tests for diagnosing lower urinary tract infections in patients with lower urinary tract symptoms but no dysuria lack sensitivity and should be abandoned, according to research published in the May issue of The Journal of Urology.
Abstract
Full Text (subscription or payment may be required)
Variables Help Guide Active Surveillance in Prostate Cancer
THURSDAY, May 13 (HealthDay News) -- Variables that are available at prostate cancer diagnosis and first surveillance biopsy during active surveillance can be used to inform men of the probability of an unfavorable biopsy, according to research published in the May issue of The Journal of Urology.
Abstract
Full Text (subscription or payment may be required)
New FDA Program Targets Misleading Drug Advertising
WEDNESDAY, May 12 (HealthDay News) -- The U.S. Food and Drug Administration has announced the launch of a new program to educate health care providers regarding their role in making certain that advertisements and promotions for prescription drugs are truthful and not misleading.
badad@fda.gov
More Information
PSA Kinetics Not Reliable in Predicting Adverse Pathology
WEDNESDAY, May 5 (HealthDay News) -- Prostate-specific antigen (PSA) velocity (PSAV) and doubling time (PSADT) do not appear to be reliable in predicting adverse pathology, and should not replace annual surveillance biopsy in men undergoing active surveillance for prostate cancer, according to a study published online May 3 in the Journal of Clinical Oncology.
Abstract
Full Text (subscription or payment may be required)
Editorial
